Source-grounded facts extracted from Dyne Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Dyne Therapeutics, Inc. reported financial results for the first quarter of 2026.
“Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today reported financial results for the first quarter of 2026 and recent business highlights.”
Dyne Therapeutics, Inc. incurred term loan of $50.0 million with Hercules Capital, Inc. at Wall Street Journal prime rate, subject to a floor of 7.50%, plus 2.45% maturing July 1, 2030.
“On December 8, 2025 (the “Amendment Closing Date”), Dyne Therapeutics, Inc. (the “Company”) entered into the First Amendment (the “First Amendment”) to Loan and Security Agreement with Hercules Capital, Inc. (“Hercules”), in its capacity as administrative agent and collateral agent (the “Agent”), and certain other financial institutions party thereto as lenders (collectively, the “Lenders”). The First Amendment amended certain of the tranche sizes and funding milestone requirements under the Loan and Security Agreement, dated as of June 27, 2025 (the “Initial Loan Agreement” and, such Initial Loan Agreement as amended by the First Amendment, the “Loan Agreement”), by and among the Company, Hercules and the Lenders and permitted the Company to borrow, as of the Amendment Closing Date, a second term loan tranche in an aggregate principal amount of $50.0 million. Following entry into the First Amendment and the borrowing of the second term loan tranche, the Company has two additional term”
Dyne Therapeutics, Inc. incurred credit facility of up to $275.0 million with Hercules Capital, Inc. at Wall Street Journal prime rate, subject to a floor of 7.50%, plus 2.45% maturing July 1, 2030.
“The Loan Agreement provides for term loans in an aggregate principal amount of up to $275.0 million under multiple tranches”
Erick Lucera was appointed as Chief Financial Officer and Treasurer at Dyne Therapeutics, Inc..
“On March 20, 2025, Dyne Therapeutics, Inc. (the “Company”) announced that its Board of Directors (the “Board”) had appointed Erick Lucera as Chief Financial Officer and Treasurer of the Company, effective as of March 31, 2025 (the “Effective Date”).”
Susanna High resigned as Chief Operating Officer at Dyne Therapeutics, Inc..
“Jonathan McNeill, M.D., the Company’s Chief Business Officer, and Susanna High, the Company’s Chief Operating Officer, each notified the Company of their intention to resign their employment.”
Jonathan McNeill, M.D. resigned as Chief Business Officer at Dyne Therapeutics, Inc..
“Jonathan McNeill, M.D., the Company’s Chief Business Officer, and Susanna High, the Company’s Chief Operating Officer, each notified the Company of their intention to resign their employment.”
Dyne Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $65.6 million, or $0.81 per basic and diluted share, EPS $0.81 per basic and diluted share.
“Net loss for the quarter ended March 31, 2024 was $65.6 million, or $0.81 per basic and diluted share.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.